Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 15Myeloid 5Lymphoid 5Classical hematology 2

Conditions

Anemia, Refractory, with Excess of Blasts 7Leukemia, Myeloid, Acute 6Myelodysplastic Syndromes 4Lymphoma, Non-Hodgkin 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Leukemia, Myelomonocytic, Chronic 3Hodgkin Disease 3Leukemia, Myeloid, Accelerated Phase 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia, Biphenotypic, Acute 2Leukemia 2Hemoglobinopathies 2Congenital Abnormalities 2Thalassemia 1Neoplasms, Plasma Cell 1Neoplasm, Residual 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Multiple Myeloma 1Lymphoma 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Leukemia, Eosinophilic, Acute 1Leukemia, Basophilic, Acute 1Immunologic Deficiency Syndromes 1Histiocytosis, Langerhans-Cell 1

Interventions

fludarabine phosphate 31Peripheral Blood Stem Cell Transplantation 26Cyclophosphamide 24Busulfan 21Cyclosporine 20Mycophenolic Acid 19Cytarabine 16Antilymphocyte Serum 15Whole-Body Irradiation 14Tacrolimus 14Radiotherapy 13Filgrastim 13Methotrexate 11Melphalan 10Etoposide 10Cord Blood Stem Cell Transplantation 9Methylprednisolone 8sargramostim 6Transplantation 5Idarubicin 5Thiotepa 4Flow Cytometry 4Daunorubicin 4Cytogenetic Analysis 4Immunologic Techniques 3Granulocyte Colony-Stimulating Factor 3Gemtuzumab 3tipifarnib 2merphos 2entinostat 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Congenital Abnormalities × Clofarabine × Classical hematology × Clear all
NCT01101880 2017-10-19

Clofarabine, Cytarabine, and Filgrastim in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome, and/or Advanced Myeloproliferative Neoplasm

University of Washington

Phase 2 Completed
50 enrolled 10 charts
Classical hematologyOther hematologic neoplasm

Congenital Abnormalities, Anemia, Refractory, with Excess of Blasts, Leukemia, Myelomonocytic, Chronic

NCT00454480 2013-08-26

Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

National Cancer Institute (NCI)

Phase 2/3 Completed
2,000 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Congenital Abnormalities, Anemia, Refractory, with Excess of Blasts, Leukemia, Erythroblastic, Acute, Leukemia, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Basophilic, Acute, Leukemia, Eosinophilic, Acute, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡